Valspodar

N/A

Report date: 2022/08/25 20:08:35
NME

Base Information

Drug NameValspodar
Drug Alias Name伐司扑达Valspodarum伐司朴达AmdraySDZ-PSC-833 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP-glycoprotein 1 inhibitors
TargetsP-glycoprotein 1
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative Diseases +[22] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[4] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWashington University School Of MedicineNational Cancer InstituteLeukemia Research Fund Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative Diseases +[22] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG